ECOG-ACRIN Staff

June 8, 2020

Now Enrolling: The DECREASE trial seeks to decrease treatment side effects – and improve quality of life – for people with early-stage anal cancer

This study is evaluating whether lower doses of chemoradiation will be able to effectively treat early-stage anal squamous cell carcinoma while also decreasing side effects.
June 7, 2020

Now Enrolling: The CompassHER2 pCR trial is determining if certain patients with early-stage HER2 positive breast cancer may benefit from reduced chemotherapy

The purpose of this study is to find out if some patients with early-stage HER2 positive breast cancer can safely be treated with less chemotherapy than is generally used.
June 6, 2020

Trial Results: ECOG-ACRIN plans to conduct a randomized phase 3 trial aimed at sparing people with oropharynx cancer unnecessary side effects from treatment, based on the recent results of phase 2 study E3311

This study showed that surgery followed by low-dose radiation alone led to very good outcomes, similar to surgery with standard-dose radiation, preserving patients’ throat function and potentially sparing them unnecessary side effects.